Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Catalyst Pharmaceuticals (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, has announced its participation in three upcoming investor conferences in September 2024. The company's management team, including CEO Richard J. Daly, will be presenting at:

• 2024 Wells Fargo Healthcare Conference on September 5 at 2:15 PM ET
• H.C. Wainwright 26th Annual Global Investment Conference on September 9 (virtual) at 7:00 AM ET
• 2024 Cantor Global Healthcare Conference on September 18 at 2:30 PM ET

Webcasts of these presentations will be available on the company's website under the Investors section, with replays accessible for at least 30 days.

CORAL GABLES, Fla., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below.

2024 Wells Fargo Healthcare Conference
Date: Thursday, September 5, 2024
Presentation: 2:15 PM ET
Webcast Link

H.C. Wainwright 26th Annual Global Investment Conference
Date: Monday, September 9, 2024 - Virtual
Presentation: Available beginning at 7:00 AM ET
Webcast Link         

2024 Cantor Global Healthcare Conference
Date: Wednesday, September 18, 2024
Presentation: 2:30 PM ET
Webcast Link         

The webcasts will be available under the Investors section on the Company's website, www.catalystpharma.com, and a replay will be available for at least 30 days.

About Catalyst Pharmaceuticals

With exceptional patient focus, Catalyst is committed to developing and commercializing innovative first-in-class medicines that address rare and difficult-to-treat diseases. Catalyst's flagship U.S. commercial product is FIRDAPSE® (amifampridine) Tablets 10 mg, approved for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS") in adults and pediatric patients 6 years of age and older. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. Most recently, on May 30, 2024, the FDA approved an increased maximum daily dose of 100 mg for FIRDAPSE for adults and pediatric patients weighing more than 45 kg.

In January 2023, Catalyst acquired the U.S. commercial rights to FYCOMPA® (perampanel) CIII, a prescription medicine approved in people with epilepsy aged four and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older.

On July 18, 2023, Catalyst acquired an exclusive license for North America for AGAMREE® (vamorolone) oral suspension 40 mg/mL, a novel corticosteroid treatment for Duchenne Muscular Dystrophy. AGAMREE previously received FDA Orphan Drug and Fast Track designations and was approved by the FDA for commercialization in the U.S. on October 26, 2023. AGAMREE became commercially available by prescription in the U.S. on March 13, 2024. Further, in July 2024, Catalyst entered into an exclusive license, supply, and commercialization agreement for AGAMREE in Canada.

For more information about Catalyst, please visit the Company's website at www.catalystpharma.com. For Full Prescribing and Safety Information for FIRDAPSE®, please visit www.firdapse.com. For Full Prescribing Information, including Boxed WARNING for FYCOMPA®, please visit  www.fycompa.com. For Full Prescribing Information for AGAMREE®, please visit  www.agamree.com.

Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.

FAQ

When is Catalyst Pharmaceuticals (CPRX) presenting at the Wells Fargo Healthcare Conference in 2024?

Catalyst Pharmaceuticals (CPRX) is presenting at the Wells Fargo Healthcare Conference on Thursday, September 5, 2024, at 2:15 PM ET.

Which investor conferences will Catalyst Pharmaceuticals (CPRX) participate in during September 2024?

Catalyst Pharmaceuticals (CPRX) will participate in three investor conferences in September 2024: the Wells Fargo Healthcare Conference, the H.C. Wainwright Global Investment Conference, and the Cantor Global Healthcare Conference.

How can investors access the webcasts of Catalyst Pharmaceuticals' (CPRX) conference presentations?

Investors can access the webcasts of Catalyst Pharmaceuticals' (CPRX) conference presentations under the Investors section on the company's website, www.catalystpharma.com. Replays will be available for at least 30 days after each event.

What is the date and time of Catalyst Pharmaceuticals' (CPRX) presentation at the 2024 Cantor Global Healthcare Conference?

Catalyst Pharmaceuticals (CPRX) will present at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 2:30 PM ET.

Is Catalyst Pharmaceuticals' (CPRX) participation in the H.C. Wainwright conference in 2024 virtual or in-person?

Catalyst Pharmaceuticals' (CPRX) participation in the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, is virtual.